1 Assessing Antimicrobial Use Patterns in Christian Health Association of Malawi (CHAM)

2 Health Facilities: A Cross-Sectional Study Protocol

3

4 Authors:

- 5 Evans Chimayi Chirambo^{1,2,3*}, Dumisani Nkhoma¹, Francis Chiumia^{3*}, Sharon Odeo⁴, Patience
- 6 Khomani⁵, Innocent Chibwe⁶, Simon Matchado⁷, Pacharo Matchere¹, Beatrice Chiweza¹, Elled
- 7 Mwenyekonde¹, Elizabeth Kampira³, Collins Mitambo⁶, & Happy Makala¹.
- 8

9 Affiliations

- 10 1. Christian Health Association of Malawi (CHAM).
- 11 2. Malawi-Liverpool Wellcome Programme (MLW).
- 12 3. Kamuzu University of Health Sciences (KUHES; formerly University of Malawi, College of
- 13 Medicine)
- 14 4. Ecumenical Pharmaceutical Network (EPN)
- 15 5. Ekwendeni College of Health Sciences (ECOHS)
- 16 6. Ministry of Health-Antimicrobial Resistance National Coordinating Centre (MOH-AMR-NCC)
- 17 7. Pharmacy and Medicines Regulatory Authority (PMRA)
- 18

19 Email addresses of authors

- 20 ECC: <u>ecchirambo@mlw.mw</u>
- 21 DN: <u>dnkhoma@cham.org.mw</u>
- 22 FC: <u>fkchiumia@kuhes.ac.mw</u>
- 23 SO: <u>sodeo@epnetwork.org</u>
- 24 PK: <u>khomanipatience@gmail.com</u>
- 25 IB: <u>inno.chibwe@gmail.com</u>
- 26 SM: <u>smatchado@pmra.mw</u>

- 27 PC: pmatchere@cham.org.mw
- 28 BC: <u>bchiweza@cham.org.mw</u>
- 29 EM: <u>emwenyekonde@yahoo.com</u>
- 30 EK: <u>ekampira@medcol.mw</u>
- 31 CM: collins.mitambo@health.gov.mw
- 32 HM: <u>hmakala@cham.org.mw</u>
- 33

34 Key Words:

- 35 Antimicrobial resistance, Antimicrobial use, Christian Health Association of Malawi, under-
- 36 served population
- 37
- 38 Running title:
- 39 A study protocol for Assessing Antimicrobial Use Patterns in Christian Health Association of
- 40 Malawi
- 41

42 Corresponding Author

- 43 Evans Chimayi Chirambo, Christian Health Association of Malawi, Lilongwe, and Malawi-
- 44 Liverpool Wellcome Programme, Blantyre, Malawi
- 45 <u>ecchirambo@mlw.mw</u>
- 46

47 Alternative corresponding author

- 48 Francis Chiumia, Pharmacy Department, School of Life Sciences and Allied Health Professions,
- 49 College of Medicine, Kamuzu University of Health Sciences, Private Bag 360, Blantyre 3,
- 50 Malawi
- 51 <u>fkchiumia@kuhes.ac.mw</u>
- 52

53 Funding

54	This work is funded by Ministry of Health Antimicrobial Resistance National Coordinating Centre		
55	(AMR-NCC). The funders were not involved in the design of the study. Additionally, they will not		
56	play any role in the implementation of this project from data collection, analysis and decision to		
57	disseminate data.		
58			
59	The sponsor for the study is Christian Health Association of Malawi (CHAM). The study		
60	sponsors were not involved in designing of the study and will not be involved in data collection,		
61	analysis and dissemination.		
62			
63	Competing Interest		
64	The authors declare no conflict of interest.		
65			
66	Data Availability		
67	This is not applicable at the moment. However, data will be made available in future.		
68			
68 69	Abstract		
68 69 70	Abstract Introduction		
68 69 70 71	Abstract Introduction The threat of antimicrobial resistance (AMR) in Malawi is high with reported mortality of 19,300		
68 69 70 71 72	Abstract Introduction The threat of antimicrobial resistance (AMR) in Malawi is high with reported mortality of 19,300 annually, the 23rd highest age-standardised mortality. One of the drivers of AMR is misuse of		
68 69 70 71 72 73	Abstract Introduction The threat of antimicrobial resistance (AMR) in Malawi is high with reported mortality of 19,300 annually, the 23rd highest age-standardised mortality. One of the drivers of AMR is misuse of antibiotics, a phenomenon that has not been adequately researched in Malawi. This study aims		
68 69 70 71 72 73 74	Abstract Introduction The threat of antimicrobial resistance (AMR) in Malawi is high with reported mortality of 19,300 annually, the 23rd highest age-standardised mortality. One of the drivers of AMR is misuse of antibiotics, a phenomenon that has not been adequately researched in Malawi. This study aims to investigate antimicrobial use patterns using prescribing, patient and facility indicators		
68 69 70 71 72 73 74 75	Abstract Introduction The threat of antimicrobial resistance (AMR) in Malawi is high with reported mortality of 19,300 annually, the 23rd highest age-standardised mortality. One of the drivers of AMR is misuse of antibiotics, a phenomenon that has not been adequately researched in Malawi. This study aims to investigate antimicrobial use patterns using prescribing, patient and facility indicators Christian Health Association of Malawi (CHAM) health facilities.		

77 Methods

78 This will be a multiple cross-sectional study which will collect data from facility (194), patients 79 (388), and prescriptions (3,104). Data will be collected using KoboToolbox v2021, and exported into Microsoft Excel version 2016 for cleaning and coding. Variables will be categorized 80 according to the antimicrobial use indicators. The study will use STATA Version 14 statistical 81 82 software for data analysis. Subsequently, facilities will be put in GPS map to show hotspots of 83 irrational antimicrobial use. The study will run from January 2024 to December 2025. 84 Discussion 85 86 This study will provide detailed information on frequently used antimicrobials, the cost of antimicrobials relative to medicine budget, the intensity of exposure to antimicrobials, the 87 availability of antimicrobials, patients' understanding of antimicrobials use, and availability of 88 89 important documents for antimicrobial use. Secondarily, the study will unravel the prevalence of 90 irrational antimicrobial use, the main factors contributing to it, and location where irrational use 91 is most prevalent. These findings will inform the national antimicrobial stewardship action plan, aiming to safeguard the available antimicrobials. 92 93 94 Ethics and Dissemination The protocol has been approved by Malawi's College of Medicine Research Ethics Committee 95 96 (COMREC) [Protocol # P.04/24-0651]. Participation in the study will be voluntary, and consent 97 and assent will be sought during data collection. Data will be handled confidentially, with 98 findings disseminated in conferences, to key AMR focused stakeholders, and finally through manuscript publication in a peer reviewed journal. 99 100 101 Registration details 102 N/A 103

104 Introduction

105 Antimicrobial resistance (AMR) has emerged as a global health crisis, posing a significant threat to the effective treatment of infectious diseases. World Health Organisation (WHO) estimates 106 that 1.27 million annual deaths are directly linked to bacterial AMR while 4.97 million annual 107 108 deaths are associated with bacterial AMR (1). It is further predicted that the global annual 109 mortality rate will reach 10 million by 2050 if no measures are taken to curb AMR (2). In Malawi, 110 3,600 deaths are directly caused by bacterial AMR annually and 15,700 deaths associated with 111 bacterial AMR, the 23rd highest age-standadised mortality rate per 100,000 population 112 associated with AMR across 204 countries (3). Unfortunately, drivers of AMR such as irrational 113 antimicrobial use are not well elucidated in Malawi. Christian Health Association of Malawi (CHAM), established in 1966, is a faith-based non-114 governmental organization which runs 194 health facilities. These health facilities are 115 116 categorized as full-fledged hospitals which are similar to a district hospital and offer specialised 117 healthcare services, community hospital which are mid-level hospitals with very few or no specialised healthcare services, and health centres which provide basic healthcare services. 118 The health facilities are distributed in 27 of 28 Malawi's political districts except Mwanza District, 119 120 and offers up to 30% of the national healthcare services, second only to the State, with more focus on poor people in hard-to-reach areas (4). 121 CHAM is one of the highest consumers of antimicrobials in Malawi. However, data is lacking on 122 123 antimicrobial use in CHAM's health facilities. Specifically, no study has looked at antimicrobial 124 use patterns such as prescribing indicators, facility indicators and patient indicators for any of CHAM's health facilities. This study aims to investigate antimicrobial use in CHAM health 125 facilities using facility, patient and prescribing indicators. Understanding the patterns of 126 127 antimicrobial use within CHAM will facilitate the development of targeted interventions to 128 promote appropriate prescribing and facility practices and optimize patient outcomes.

129

130 **Objectives**

- 131 The broad objective
- 132 To investigate whether antimicrobials are properly used using prescribing, facility and patient
- 133 indicators.
- 134
- 135 The specific objectives
- 136 1. To find out the extent of antimicrobial use based on prescribing, facility and patient indicators.
- 137 2. To measure the prevalence of irrational use of antimicrobials using facility, prescribing, and
- 138 patient indicators.
- 139 3. To identify two for each of facility, patient and prescribing indicators that increase irrational
- 140 use of antimicrobials.
- 4. To map-out health facilities with irrational use (irrational use above WHO set percentage of
- 142 irrational use) of antimicrobial.
- 143

144 Methods

- 145 Study Aim
- 146 This study seeks to identify shortcomings and areas for improvement in antimicrobial use
- 147 practices. The insights gained from this analysis will be invaluable in guiding the development
- and implementation of targeted interventions aimed at optimizing antimicrobial usage,
- 149 combating AMR, and ultimately enhancing patient care outcomes. Additionally, the study will
- 150 provide a basis for formulation of key policies and intensification of regulations in antimicrobial

151 use.

152

153 Study Design:

154	This will be a multiple cross-sectional study design. The study will collect primary data on			
155	prescribing indicator, facility indicator and patient indicator as per inclusion and exclusion			
156	criteria.			
157	Study Setting and sites			
158	The study will collect data from CHAM health facilities. These health facilities are located in 27			
159	of 28 political districts of Malawi (Figure 1). These health facilities are evenly distributed in the			
160	throughout country, with the majority located at an average distance of over eight kilometres			
161	from the nearest health facility (be it CHAM or State's owned). Ninety-percent. Ninety percent			
162	of these health facilities are located in rural and hard-to-reach areas.			
163				
164	The study will be coordinated from CHAM Secretariat in Lilongwe, the Capital City of Malawi.			
165	Additionally, data cleaning, analysis and dissemination will be planned and executed from the			
166	Secretariat.			
167				
167 168	Participants Characteristics (Sample Size and Selection)			
167 168 169	Participants Characteristics (Sample Size and Selection) The study will collect data from the 194 CHAM health facilities for facility indicator. As for			
167 168 169 170	Participants Characteristics (Sample Size and Selection) The study will collect data from the 194 CHAM health facilities for facility indicator. As for prescribing indicator, the sample size is 3,104 prescriptions, 16 per health facility. The 3,000			
167 168 169 170 171	Participants Characteristics (Sample Size and Selection) The study will collect data from the 194 CHAM health facilities for facility indicator. As for prescribing indicator, the sample size is 3,104 prescriptions, 16 per health facility. The 3,000 prescriptions are as per World Health Organisation (WHO) recommendation for a cross-			
167 168 169 170 171 172	Participants Characteristics (Sample Size and Selection) The study will collect data from the 194 CHAM health facilities for facility indicator. As for prescribing indicator, the sample size is 3,104 prescriptions, 16 per health facility. The 3,000 prescriptions are as per World Health Organisation (WHO) recommendation for a cross- sectional study of a prescribing indicator study (5) and the 104 are for withdrawal of consent,			
167 168 169 170 171 172 173	Participants Characteristics (Sample Size and Selection) The study will collect data from the 194 CHAM health facilities for facility indicator. As for prescribing indicator, the sample size is 3,104 prescriptions, 16 per health facility. The 3,000 prescriptions are as per World Health Organisation (WHO) recommendation for a cross- sectional study of a prescribing indicator study (5) and the 104 are for withdrawal of consent, incomplete responses, and closure of the facilities as well as collecting data from 16			
167 168 169 170 171 172 173 174	Participants Characteristics (Sample Size and Selection) The study will collect data from the 194 CHAM health facilities for facility indicator. As for prescribing indicator, the sample size is 3,104 prescriptions, 16 per health facility. The 3,000 prescriptions are as per World Health Organisation (WHO) recommendation for a cross- sectional study of a prescribing indicator study (5) and the 104 are for withdrawal of consent, incomplete responses, and closure of the facilities as well as collecting data from 16 prescriptions per facility. The 3,104 prescriptions will provide enough data to determine extent of			
167 168 169 170 171 172 173 174 175	Participants Characteristics (Sample Size and Selection) The study will collect data from the 194 CHAM health facilities for facility indicator. As for prescribing indicator, the sample size is 3,104 prescriptions, 16 per health facility. The 3,000 prescriptions are as per World Health Organisation (WHO) recommendation for a cross- sectional study of a prescribing indicator study (5) and the 104 are for withdrawal of consent, incomplete responses, and closure of the facilities as well as collecting data from 16 prescriptions per facility. The 3,104 prescriptions will provide enough data to determine extent of antimicrobial use and detect irrational prescribing of antimicrobial in CHAM health facilities.			
167 168 169 170 171 172 173 174 175 176	Participants Characteristics (Sample Size and Selection) The study will collect data from the 194 CHAM health facilities for facility indicator. As for prescribing indicator, the sample size is 3,104 prescriptions, 16 per health facility. The 3,000 prescriptions are as per World Health Organisation (WHO) recommendation for a cross- sectional study of a prescribing indicator study (5) and the 104 are for withdrawal of consent, incomplete responses, and closure of the facilities as well as collecting data from 16 prescriptions per facility. The 3,104 prescriptions will provide enough data to determine extent of antimicrobial use and detect irrational prescribing of antimicrobial in CHAM health facilities. Patient indicator sample size is 275 patients as per cross-sectional study formula (6) with			
167 168 169 170 171 172 173 174 175 176 177	Participants Characteristics (Sample Size and Selection) The study will collect data from the 194 CHAM health facilities for facility indicator. As for prescribing indicator, the sample size is 3,104 prescriptions, 16 per health facility. The 3,000 prescriptions are as per World Health Organisation (WHO) recommendation for a cross- sectional study of a prescribing indicator study (5) and the 104 are for withdrawal of consent, incomplete responses, and closure of the facilities as well as collecting data from 16 prescriptions per facility. The 3,104 prescriptions will provide enough data to determine extent of antimicrobial use and detect irrational prescribing of antimicrobial in CHAM health facilities. Patient indicator sample size is 275 patients as per cross-sectional study formula (6) with assumptions of standard normal variate (<i>Z</i>) of 1.96, expected proportion from previous study of			

179 consent, closure of facility and incomplete data, and to collect data from 2 patients per facility.180 This leads to a total of 388 patients for patient indicator data.

181

The study will collect data from all facilities for facility indicator data while systematic random 182 sampling will be implemented for prescribing and patient indicators' data. For prescription 183 184 indicator data, each ward will contribute an equal number of participants, chosen from every even number of patient until the 16th prescriptions. The patient indicator data will be collected 185 186 from every odd number of the prescribing indicator data. Subsequent patient indicator data 187 collection will utilize a new set of odd numbers for each facility. For example, if 1 and 3 were initially selected, the next round would include 5 and 7, then 9 and 11, restarting the cycle upon 188 reaching the 15th number out of the 16 prescriptions per facility. 189

190

191 Data collection

Two trained personnel will collect data for each facility; pharmacy profession will collect prescribing and facility indicators data while a clinician will collect patient data. The study will use three online questionnaires, one for each indicator, on KoboToolbox v2021.2.4. Facility indicator data will be the first to collect. This will followed by simultaneous collection of patient and prescribing indicators' data.

197

198 The study will collect data from a facility which will be opened and operational on the day of data

199 collection (all facilities closed or suspended services during data collection). Additionally,

200 prescribing indicator data will come from legible patient files less than a month and for patients

aged 6 and above. The age for prescribing indicator will be inclusion for patient indicators' data.

202 Patients in intensive care will be excluded from the study.

203

204 Study Outcome

205	For prescribing indicator, the study will provide the extent of antimicrobial use through
206	percentage of hospitalization with one or more antimicrobial used and average number of
207	antimicrobials prescribed per hospitalization in which antimicrobials were prescribed.
208	Furthermore, the findings will include average cost of antimicrobials prescribed per
209	hospitalization, average duration of prescribed antimicrobial treatment for intensity of exposure
210	to antimicrobial, percentage of antimicrobials prescribed consistent with the hospital formulary
211	list and by generic name to measure the degree of conformity to national prescribing policies,
212	and average number of drug encounter to measure the degree of polypharmacy.
213	
214	The patient indicator data outcome are percentage of prescribed antimicrobials actually
215	administered or dispensed to a patient, average consultation and dispensing time, percentage
216	of medicines actually dispensed, percentage of medicines adequately labelled, and percentage
217	of patients' correct dose. The facility indicator will provided existence of Standard Treatment
218	Guidelines (STG) and Essential Medicines List (EML), availability of key antimicrobials in the
219	hospital, average number of days that a set of key antimicrobials is out of stock, and percentage
220	antimicrobial expenditure of hospital medicines cost.
221	
222	Overall, the study will provide prevalence of irrational use of antimicrobial, main drivers of
223	irrational antimicrobial use, and geographical distribution of irrational use of antimicrobials in
224	CHAM health facilities.
225	
226	Data Management Plan
227	This data from KoboToolbox v2021.2.4 will be downloaded to Microsoft Excel Version 2016,
228	cleaned and coded. The data will be stored on a password-protected computer, and access will
229	be restricted to only study team, and relevant authority under full authorization of the PI. The
230	data will not be connected to patients as numbers and letters will be used to identify

- 231 participants. Data will be archived for any future research and participants will assent and
- consent to the future use of data for research purposes.
- 233
- 234 Safety Plan
- 235 This is an observational study hence there are no direct safety concerns from the study
- approach. However, data collecting team will call upon clinical team to attend to any patient
- requiring clinical attention while responding to the study.
- 238
- 239 Data Type and Statistical Analysis

240 Statistical analysis will be performed using STATA SE version 14. The data analysis will include

frequencies, mean, standard deviation (SD) and percentage to describe data distribution and

spread. Additionally, the study will use one-way analysis of variance (ANOVA) for numerical

243 data and Pearson's chi-squared or fisher's exact (depending on the cell number) tests for

categorical data, to check for association among different variables. P-value less than 0.05 will

be considered statistically significant at 95% confidence interval for all data.

246

247 Ethical Considerations and Declarations

248 The protocol has been approved by College of Medicine Research Ethics Committee

249 (COMREC) on 15th May 2024 [protocol number P.04/24-0651]. Prescriptions, patients and

250 health facilities will be identified by numbers. Consent will be sought from adults while assent

will be obtained for children. Participation in the study will be voluntary. Additionally, before

commencing data collection, data collecting team will get approval from each health facility

253 management team. The study team will also get approvals from the facility in-charges before

commencement of the study.

255

256 Study Status and Timeline

The study will run from January 2024 to December 2025. Currently, the implementation is at

258 preparatory stage which will be followed by pre-testing the questionnaires then data collection

259 up-to data dissemination (**Figure 2**).

260 Discussion

261 Study Limitations and Challenges

262 The study will involve self-reporting and review of documents which might introduce errors

263 because of the knowledge level of the reporter or the quality of documentation, possibly

affecting the accuracy and quality of collected data. To overcome this, multiple data sources

such as patients, patient file, health passport and input from the clinical team will be used.

Additionally, data from patient files and health passport may be incomplete or inaccurate

267 because of unclear handwriting or poorly recorded information. This will be addressed by

268 excluding prescriptions with poor handwriting or incomplete records.

269

270 Logistics challenge is a concern for CHAM health facilities which are mostly in remote areas.

271 This will be addressed by effective planning and communication, using a combination of multiple

communication channels. Additionally, the study involves managing and analyzing large volume

of data. This will be mitigated by thoroughly training data reporters to ensure collected data

requires minimal cleaning, and by using KoboToobox to reduce most of the manual work

275 required for data entry.

276

277 Dissemination plan

The findings will be shared to all CHAM facilities at CHAM Annual General Meeting (AGM), the MOH AMR Sub technique working group (TWG) and Kamuzu University of Health Sciences (KUHES) Research Dissemination Conference. Additionally, the study will be presented in other local and international conferences on AMR. Finally, the study findings will be considered for publication in peer reviewed journals.

ົ	o	ົ
	×	-
~	o	ັ

284 Study Amendment and Termination

- 285 Study alterations will be done in full consultation with all study investigators with approval from
- ethical oversight committee. In the end, we will provide reports and communication to all key
- stakeholders in the project following termination of the study.
- 288

289 Authors Contribution

- 290 ECC will lead and coordinate all activities as the chief investigator. DN and FC will handle all
- 291 write-ups, project planning and implementation. SO, PK, SM will review, collect and analyse,
- and draft report and journal article. PM, EM, EK, CM, and HM will serve as overall study
- supervisors, providing leadership, reviews and coordinating resources for the study.

294

295 Acknowledgements

- 296 We thank CHAM's management for authorizing the implementation of this study in the
- 297 organisation's health facilities.

298

299 Support Information

- 300 Ethical approvals from Malawi's COMREC, and authorization letter from CHAM to conduct the
- 301 study in the organisation's health facilities.

302

303 References

- 304. Antimicrobial Resistance: Briefing to WHO Member States. World Health Organsiation
- 305 [Internet]. 2023 March 22. Available from: chrome-
- 306 extension://efaidnbmnnnibpcajpcglclefindmkaj/<u>https://apps.who.int/gb/MSPI/pdf_files/2023/03/lt</u>
- 307 <u>em1 22-03.pdf</u>.

- 302. O'neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Rev
- 309 Antimicrob Resist. 2014.
- 316. The burden of antimicrobial resistance (AMR) in Malawi. University of Washington [Internet].
- 311 2023. Available from: chrome-
- 312 extension://efaidnbmnnnibpcajpcglclefindmkaj/<u>https://www.healthdata.org/sites/default/files/202</u>
- 313 <u>3-09/Malawi.pdf</u>.
- 314. Malawi CHAo. About CHAM Lilongwe: Christian Health Association of Malawi; 2023 [updated
- 315 31 March 2021; cited 2024 1 January]. Available from: <u>https://cham.org.mw/about-cham/</u>.
- 316. Organisation WH. How to Investigate Drug Use in Health Facilities1993 28 June 2023 [cited
- 317 2023 28 June]. Available from: chrome-
- 318 extension://efaidnbmnnnibpcajpcglclefindmkaj/<u>https://apps.who.int/iris/bitstream/handle/10665/6</u>
- 319 <u>0519/WHO_DAP_93.1.pdf</u>.
- 326. Charan J, Biswas T. How to calculate sample size for different study designs in medical
- 321 research? Indian J Psychol Med. 2013;35(2):121-6.
- 327. Mboya EA, Sanga LA, Ngocho JS. Irrational use of antibiotics in the Moshi Municipality Northern
- 323 Tanzania: a cross sectional study. Pan Afr Med J. 2018;31:165.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit It is made available under a CC-BY-NC 4.0 International license.



A CHAM health facility

Figure 1: CHAM health facilities distributed across Malawi including facilities at Likoma Island.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit It is made available under a CC-BY-NC 4.0 International license.



Figure 2: Gantt chart of the study timelines.